Danica Yang, OD
Corneal and Contact Management · Cranford, NJNPI 1013401736
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,285 of the $6,529 with a category attached, or 65.6%. It is spread thinly across 21 manufacturers, the largest accounting for just 21.1%. Reporting peaked in 2019 at $3,452 and has fallen 80.2% since, to $683 in 2025.
Across 142 payments — averaging $45.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Valley Contax, Inc.$1K
- Alcon$1K
- Glaukos Corporation$507
- Bausch & Lomb Americas Inc.$477
- Tarsus Pharmaceuticals, Inc.$424
- AbbVie$326
- plus $2K from 15 others
What the payments were for
- Consulting fees$4006%
- Speaking & faculty fees$2003%
- Travel & lodging$1,61625%
- Food & beverage$4,28566%
- Gifts$290%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Valley Contax, Inc. | 3 | $1,376 |
| Alcon | 18 | $1,340 |
| Glaukos Corporation | 5 | $507 |
| Bausch & Lomb Americas Inc. | 22 | $477 |
| Tarsus Pharmaceuticals, Inc. | 11 | $424 |
| AbbVie(2 entities) | 14 | $326 |
| Coopervision Inc. | 5 | $299 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $247 |
| Johnson & Johnson Vision Care, Inc. | 4 | $220 |
| Sun Pharmaceutical Industries Inc. | 4 | $187 |
| Mallinckrodt Hospital Products Inc. | 12 | $187 |
| Kala Pharmaceuticals, Inc. | 10 | $148 |
| Novartis | 10 | $146 |
| Harrow Eye, LLC | 3 | $136 |
| Sight Sciences, Inc. | 1 | $129 |
| Shire North American Group Inc | 1 | $125 |
| Oyster Point Pharma, Inc. | 7 | $118 |
| Dompe US, Inc. | 5 | $83 |
| Biotissue Holdings Inc. | 1 | $24 |
| Rayner Intraocular Lenses Limited | 1 | $17 |
| Aerie Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CE-marked KXLA system$298
- XDEMVY$268
- AcrySof$251
- XIIDRA$250
- KXL System$141
- Photrexa$141
- TearCare$129
- Acuvue$125
- AIR OPTIX$125
- Biofinity Contact Lens$125
- MIEBO$125
- TRYPTYR$125
- CEQUA$124
- VUITY$100
- VEVYE$100
How this compares
$6,529 in reported general payments places this provider in the 85th percentile of 45 corneal and contact management providers in New Jersey.
See all corneal and contact management providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 15 | $16,680 |
| RestasisCyclosporine | 13 | $8,234 |
| Prednisolone Acetate | 26 | $1,496 |
| Latanoprost | 48 | $1,271 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 20 | $338 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 19 | $220 |
| Timolol Maleate | 15 | $128 |
| Azelastine Hcl | 13 | $120 |
| Dorzolamide Hcl | 11 | $49 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra | $477 | $16,68015 claims |
| AbbVieRestasis | $326 | $8,23413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 45 corneal and contact management providers in New Jersey.
Other corneal and contact management in Cranford
- Bradford RippsLake Hopatcong$94K
- Vittorio MenaFairview$53K
- Kenneth DanielsLambertville$14K
- Thomas ConroyBloomfield$9K
- Alan SchlusselWest Orange$8K
- Daniel IsaacCherry Hill$5K
- Amy SteinParamus$4K
- Paul DifioreMount Laurel$3K
- Jeffrey CaseFreehold$3K
- Saras RustagiWest New York$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.